Issues: Vax Specific

Anthrax

Hepatitis B

Hib

HPVPV

Influenza

Lyme Disease
Meningococcal

MMR    

Polio

Rotavirus

● Smallpox

Tdap/Td

Varicella

Yellow Fever

 

Issues: Misc

Exemptions

Legislation 

New Vax Status

Thimerosal

Independent Vax  Safety Board

 

Vaccine Info

2008 Schedule

ACIP Recs

Components
IOM Reports

● Vax Injury Comp Program
Manufacturer Links

Package Inserts

Reporting AEs

Thimerosal Table

VAERS

VISs

 

Links
 

Search
 

About IVS

Faculty Biographies

Publications

Donations

 

Email IVS

 

Disclaimers & Privacy
 

 

Institute for Vaccine Safety

Johns Hopkins Bloomberg School of Public Health

615 N. Wolfe Street

Room W5041

Baltimore, MD 21205

www.vaccinesafety.edu

 
 
 

INFLUENZA VACCINE

  • The US FDA approved FluMist, by MedImmune, for use in people 2-49 years of age.  This expansion now includes children 2-5 years of age.  FDA Press Release (9-19-07)

  • The US FDA approved Glaxo SmithKline's FluLaval influenza virus vaccine. FluLaval is for adults 18 years and older to protect against strains of influenza projected to impact the Northern Hemisphere in the 2006/07 flu season. FluLaval is manufactured by ID Biomedical Corp (a Canadian subsidiary of GlaxoSmithKline) and distributed by GSK. FDA Press Release (10-05-06)

  • The US FDA announces approval of Fluarix, an inactivated influenza vaccine for adults. Fluarix is manufactured in Germany by a subsidiary of GlaxoSmithKline.  FDA Press Release (08-31-05)

  • CDC's guidelines for controlling influenza transmission in long-term care facilities (06-06-05).  PDF (150k) | HTML version

  • A new Influenza vaccine will be available for the 2005/6 Flu Season:  The FDA has approved the license supplement of sanofi pasteur (formerly Aventis Pasteur) to market a formula of their influenza vaccine produced without introducing preservatives at any step in the manufacturing process. Fluzone®, Influenza Virus Vaccine, No Preservative, Pediatric Dose is the only influenza vaccine approved for use in the U.S. in children as young as 6 months. The vaccine will be available in 0.25 mL pediatric dose and 0.50 mL for children 3 years and older. complete press release (03-09-05)

  • CDC's National Immunization Program's Influenza Vaccine Bulletin with information on the latest developments.

  • The Centers for Disease Control and Prevention has added a web page called "Influenza (Flu) Protect Yourself & Your Loved Ones" containing a wide variety of information and updates on influenza including the map shown below. 

 

This page was last updated on November 03, 2008

© 2008 Institute for Vaccine Safety